Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. - Wikidata - awgldk - TriplyDB

Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

http://www.wikidata.org/entity/Q34356116

about

Detection and Quantification of the Fragile X Mental Retardation Protein 1 (FMRP)Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT score Towards translational therapies for multiple system atrophy Ebolavirus nucleoprotein C-termini potently attract single domain antibodies enabling monoclonal affinity reagent sandwich assay (MARSA) formulation.Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice A generic method for design of oligomer-specific antibodies.A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.Toxic species in amyloid disorders: Oligomers or mature fibrils.The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.A quantitative homogeneous assay for fragile X mental retardation 1 protein.AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson's disease diagnosis.Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.Extracellular α-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane.Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as Diagnostic Tools.

P2860

Q28079967-9E4DD5A2-20C0-4FDB-9443-332D857819EB Q28082380-E8293E6B-D655-4512-8E5D-689701DA0AF0 Q29048624-DF17DAFF-6AFD-4306-BBDF-E02260D88908 Q33797532-3BBB9262-C993-4D52-999A-341833C293CC Q34664182-512A5BB4-D288-4705-8848-335AE2A57A4A Q34692633-3326E615-FC02-4039-B48A-E4513A7D5990 Q35117526-CBDB64C4-8565-40DD-89BF-99E648346803 Q36109452-C8E79AE8-6545-4BEE-B993-1C0771ACD2DC Q37388974-07408C89-AFBC-4649-AB4A-384773363431 Q38505323-5ADCA64B-27FE-4E21-B345-7054521BB1D2 Q38575114-775891E2-9C5E-46DB-B908-B51875B580B1 Q38603309-2C7C5D20-74D1-4611-BB2B-4910F78DD9E1 Q38786158-F8885DCE-8844-4F58-8FAE-199773AD95CB Q39366291-A79DC2FC-DC90-4191-A7C3-5C4DEC65E40F Q40099259-CF1425B0-0933-4B60-B45C-EC6C3E446E62 Q42347600-14D7A467-6463-4AE8-9AED-80ADE724D6A1 Q43089495-5561C789-99ED-40A2-B529-9C7BA264E9A6 Q47941297-BA7EC8CC-734A-47AC-8AB4-58F8439AAA42 Q48335373-29D62B5A-3390-4A41-A204-D99225628740 Q55307741-68ED139E-A3B4-4E81-94D7-0BA7A56F0A10

P2860

Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

http://www.wikidata.org/entity/Q34356116

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Novel one-step immunoassays to ...... and high-throughput screening.

@ast

Novel one-step immunoassays to ...... and high-throughput screening.

@en

Novel one-step immunoassays to ...... and high-throughput screening.

@nl

type

label

Novel one-step immunoassays to ...... and high-throughput screening.

@ast

Novel one-step immunoassays to ...... and high-throughput screening.

@en

Novel one-step immunoassays to ...... and high-throughput screening.

@nl

prefLabel

Novel one-step immunoassays to ...... and high-throughput screening.

@ast

Novel one-step immunoassays to ...... and high-throughput screening.

@en

Novel one-step immunoassays to ...... and high-throughput screening.

@nl

P1433

Q34356116-352E8D7F-915A-4D84-BD2B-BE36EF1BB397

P1476

Q34356116-C0775344-6597-4B51-9D40-48272FA3FB47

P2093

Q34356116-137DA25D-922C-4362-A882-8182E1FE046E

Q34356116-13E17AC2-6544-4A41-9B67-A638E808FC5C

Q34356116-2F409F10-8314-4092-9D66-9193047D2456

Q34356116-318DB918-599E-43A5-9D04-1317879A0A46

Q34356116-6AAA546B-C61D-448C-92F5-57643FD175AF

Q34356116-A44F8D3E-B733-4300-9947-1AC55224981C

Q34356116-F1A2ADAF-7812-4800-B401-9B0158BEFE8B

P2860

Q34356116-033F93AA-BD9A-4918-A348-3BA4A87CEE66

Q34356116-049540A3-6671-47C0-B210-B4695373FB82

Q34356116-0E53DDFE-CC85-41C3-A612-9F5E2CAB90A0

Q34356116-0F87A518-9A63-4A73-A927-800B8D05D5FD

Q34356116-0FD77F93-D53F-44AC-9498-7284E0445ED6

Q34356116-10411E52-62B0-429A-8109-98CD22010C10

Q34356116-1058F8FE-B89A-40AB-A33F-4F3E0367D53D

Q34356116-1351EE5D-E7D8-4482-B98C-F943602EB69B

Q34356116-15AA9604-C4E8-432B-8D05-D3E4DFC35CD3

Q34356116-1AD5DCCE-03D9-4DAD-A5D2-42807AF364B2

P304

Q34356116-08B08E58-2608-4FE8-BBE7-0FD8CAF1A872

P31

Q34356116-4EA95C46-D915-4C85-8FB9-2E55E21C7D65

P356

Q34356116-71E16DB3-08D5-48DC-939A-8D4784F23E55

P407

Q34356116-506AB53A-FA1C-428E-9593-A5A61B36F0C5

P433

Q34356116-E1AB401F-CDBD-4D12-A520-7765BC5B8059

P478

Q34356116-27C8E38D-46D8-42AD-824B-FDA3DCD7E135

P50

Q34356116-CC28765E-83F2-4107-AE69-FD89FD574EFB

P577

Q34356116-E7F18544-63C6-4F4D-B7D0-143BC69AD9FC

P698

Q34356116-087E11CF-A101-4D38-82DC-EB87066B0C4D

P921

Q34356116-91ED1BB6-D2FA-41F0-95B9-DDE33E9850F3

Q34356116-DAE3C40B-2A76-44F0-B914-06F4BFB13FA8

P932

Q34356116-550226B6-D609-4E75-8106-2CB2FE77AA37

P356

JBC.M112.379792

P1433

Journal of Biological Chemistry

P1476

Novel one-step immunoassays to ...... and high-throughput screening.

@en

P2093

Andreas Weiss

http://www.w3.org/2001/XMLSchema#string

David Marcellin

http://www.w3.org/2001/XMLSchema#string

Derya R Shimshek

http://www.w3.org/2001/XMLSchema#string

Gregor P Lotz

http://www.w3.org/2001/XMLSchema#string

Michael Bidinosti

http://www.w3.org/2001/XMLSchema#string

Michael G Schlossmacher

http://www.w3.org/2001/XMLSchema#string

Tatjana Schweizer

http://www.w3.org/2001/XMLSchema#string

P2860

Diacylglycerol kinase theta binds to and is negatively regulated by active RhoA

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models

Neuropathology in mice expressing mouse alpha-synuclein

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

alpha-Synuclein locus triplication causes Parkinson's disease

Alpha-synuclein in Lewy bodies

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Diacylglycerol kinases: at the hub of cell signalling

Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.

P304

33691-33705

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M112.379792

http://www.w3.org/2001/XMLSchema#string

P407

P433

40

http://www.w3.org/2001/XMLSchema#string

P478

287

http://www.w3.org/2001/XMLSchema#string

P50

Brit Mollenhauer

P577

2012-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22843695

http://www.w3.org/2001/XMLSchema#string

P921

P932

3460466

http://www.w3.org/2001/XMLSchema#string